L-tyrosine sustained release
Selected indexed studies
- Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression. (CPT Pharmacometrics Syst Pharmacol, 2024) [PMID:38532525]
- PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease. (Int J Mol Sci, 2023) [PMID:36902115]
- Sustained-release levodopa. (Lancet, 1973) [PMID:4122780]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Sustained-release levodopa. (1973) pubmed
- The on-off phenomenon. (1989) pubmed
- New levodopa therapeutic strategies. (2016) pubmed
- Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression. (2024) pubmed
- PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease. (2023) pubmed
- Hot-melt extrusion based sustained release ibrutinib delivery system: An inhibitor of Bruton's Tyrosine Kinase (BTK). (2021) pubmed
- Synaptic plasticity via receptor tyrosine kinase/G-protein-coupled receptor crosstalk. (2024) pubmed
- Prolonged Release of IL-10 From Enzyme-Mediated Poly-l-(Tyrosine-co-Phenylalanine) Nanocrystals Enhances Stability and Modulates Inflammatory Responses. (2026) pubmed
- Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort. (2021) pubmed
- IPX066 , a mixed immediate/sustained-release levodopa preparation for Parkinson's disease. (2014) pubmed